RxDoctor Payments Data

John Sullivan, MD

Neurology · Fort Myers, FLNPI 1356353965

Payments from drug & device makers

$13,327in general payments, 2019–2025

Across 699 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novartis$1K
  • Amgen$906
  • GE HealthCare$775
  • UCB, Inc.$718
  • AstraZeneca$622
  • plus $8K from 54 others

What the payments were for

  • Speaking & faculty fees$580%
  • Food & beverage$13,21399%
  • Education$560%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)92$1,502
Novartis67$1,030
Amgen(2 entities)48$906
GE HealthCare42$775
UCB, Inc.26$718
AstraZeneca(2 entities)26$622
Biogen29$608
Acadia Pharmaceuticals Inc34$473
Argenx US, Inc.20$456
TG Therapeutics, Inc.7$352
Lundbeck LLC16$338
Neurelis, Inc.19$330
Sanofi15$309
Genentech USA, Inc.17$277
Pfizer15$257
MDD US Operations, LLC12$254
Teva Pharmaceuticals USA, Inc.11$221
Eisai Inc.8$219
Sunovion Pharmaceuticals Inc.15$209
Takeda Pharmaceuticals U.S.A., Inc.7$191
Acorda Therapeutics, Inc8$188
Bristol Myers Squibb8$178
Adamas Pharmaceuticals, Inc.9$175
Catalyst Pharmaceuticals, Inc.8$168
Lilly USA, LLC11$166
Biohaven Pharmaceutical Holding Company Ltd.14$165
EMD Serono, Inc.9$157
SK Life Science, Inc.6$147
Jazz Pharmaceuticals Inc.1$128
Avanir Pharmaceuticals, Inc.8$126
Biohaven Pharmaceuticals, Inc.8$126
Octapharma USA, Inc.7$124
Johnson & Johnson(2 entities)6$122
Neurocrine Biosciences, Inc.5$117
Alnylam Pharmaceuticals Inc.5$108
Otsuka America Pharmaceutical, Inc.5$107
Avion Pharmaceuticals6$95
Amneal Pharmaceuticals LLC5$79
Upsher-smith Laboratories LLC5$72
CSL Behring3$68
Grifols USA, LLC3$66
Aucta Pharmaceuticals, Inc.3$54
Sumitomo Pharma America, Inc.3$53
Insightec,inc3$52
Corium, LLC2$46
Sanofi-aventis U.S. LLC3$45
Kyowa Kirin, Inc.2$40
Almatica Pharma LLC2$37
Ipsen Biopharmaceuticals, Inc2$34
Revance Therapeutics, Inc.1$28
Greenwich Biosciences, Inc.2$27
Vanda Pharmaceuticals Inc.1$27
Scilex Pharmaceuticals Inc.1$24
C2n Diagnostics, LLC1$19
Impel Pharmaceuticals Inc.1$18
Aprecia Pharmaceuticals, LLC1$18
Merz Pharmaceuticals, LLC1$17
Sandoz1$16
Merz North America, Inc.1$16
Servier Pharmaceuticals LLC1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,327 in reported general payments places this provider in the 65th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$743,121
Medicare patients
1,403
Services billed
30,779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5012$251,544
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5014$231,813
EpidiolexCannabidiol (Cbd)12$64,378
BriviactBrivaracetam22$61,578
NuplazidPimavanserin Tartrate12$59,597
AptiomEslicarbazepine Acetate13$58,405
QuliptaAtogepant44$50,992
RytaryCarbidopa/Levodopa28$47,736
GocovriAmantadine Hcl15$41,965
UbrelvyUbrogepant21$29,251
Nurtec OdtRimegepant Sulfate16$29,212
TopamaxTopiramate11$22,008
Aimovig AutoinjectorErenumab-Aooe17$16,946
XcopriCenobamate12$15,426
Emgality PenGalcanezumab-Gnlm13$11,596

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$68$231,81314 claims
AbbVieQulipta, Ubrelvy$1,502$80,24365 claims
UCB, Inc.Briviact$718$61,57822 claims
Acadia Pharmaceuticals IncNuplazid$473$59,59712 claims
Sunovion Pharmaceuticals Inc.Aptiom$209$58,40513 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$79$52,19981 claims
MDD US Operations, LLCGocovri$254$41,96515 claims
PfizerNurtec Odt, Dilantin$257$34,03331 claims
SK Life Science, Inc.Xcopri$147$15,42612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,434 neurology providers in Florida.

Other neurology in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →